CytomX Therapeutics is a US oncology biopharmaceutical company that specialises in developing antibody therapeutics aimed at treating cancer using its innovative Probody technology platform. The range of treatments under development include CX-2009 for the treatment of breast cancer, CX-2029, which is in Phase II clinical trials for the treatment of several cancers, and BMS-986249 and BMS-986288 which target metastatic melanoma and solid tumors respectively. The company has several strategic partnerships with AbbVie Ireland, Amgen, Bristol-Myers Squibb, ImmunoGen, Pfizer and Astellas Pharma.